Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the...

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes (T2D) is characterized by progressive beta-cell dysfunction.
• Understanding how glucose-lowering medications impact beta-cell function is crucial for managing T2D.
• Model-based assessment offers detailed insights into specific components of beta-cell function.

Purpose of the Study:

• To assess changes in model-based beta-cell function parameters with different glucose-lowering treatments in T2D.
• To determine the association between these beta-cell function parameters and glycemic deterioration.

Main Methods:

• Analysis of data from the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (N = 4,712).
• Mathematical modeling of oral glucose tolerance tests to derive beta-cell function parameters (ISR, glucose sensitivity, rate sensitivity, potentiation).
• Assessment at baseline and 1, 3, and 5 years post-randomization to insulin glargine, glimepiride, liraglutide, or sitagliptin (added to metformin).
• Statistical analysis using linear mixed-effects models, Cox proportional hazards, and CART analyses.

Main Results:

• All treatments showed initial increases in beta-cell function parameters at year 1, followed by a decline.
• Liraglutide demonstrated the most significant improvements in insulin secretion rate (ISR), glucose sensitivity, and potentiation.
• Sitagliptin improved glucose sensitivity, while glimepiride and glargine had temporary or specific effects on other parameters.
• Higher baseline beta-cell function parameters were associated with protection against glycemic deterioration.

Conclusions:

• Glucose-lowering medications differentially affect specific components of beta-cell function in T2D.
• Impaired beta-cell function is linked to earlier glycemic failure, irrespective of the treatment used.
• Beta-cell function tends to decline progressively after an initial period of improvement with these therapies.